Pharmaceutical industry
Glenmark Generics Inc., USA, a subsidiary of Glenmark Pharmaceuticals, has been granted final approval by the United States Food and Drug Administration (U.S.FDA) for its generic version of Micronor tablets, a progestin-only oral contraceptive. This is the company's third female hormonal product approval and second approval
Pharmaceutical industry
India's Glenmark Pharmaceuticals has settled a patent litigation with US-based Merck & Co over its cholesterol lowering generic drug 'Ezetimibe', a generic version of Merck's patented drug 'Zetia'. The settlement allows Glenmark to launch its product in the US market, potentially earning
Pharmaceutical industry
Merck & Co. has settled a patent dispute with Glenmark Pharmaceuticals regarding the cholesterol drug Zetia, one of Merck's best-selling products. The lawsuit had been scheduled to go to trial, but the parties have agreed to a settlement that allows Glenmark to start selling its generic version of
Pharmaceutical industry
A $22.5 million settlement has been reached by Connecticut and other states against three drug companies, resolving allegations that they illegally blocked cheaper, generic versions of TriCor, a cholesterol drug, from entering the market. The settlement resolves a 2008 lawsuit filed by Connecticut and 24 other states against Abbot
Pharmaceutical industry
The Indian pharma major Wockhardt has made significant strides in the treatment of Alzheimer's disease and dementia, receiving tentative approval from the US Food & Drug Administration (US FDA) to market its version of Memantine HCl tablets. This development comes as a result of Wockhardt's settlement
Walmart Inc.
Wal-Mart launched its cheap prescription drug program in Florida two months ago and has since added 26 states, including Colorado. The program offers hundreds of generic drugs for $4, but due to Colorado's predatory pricing laws, 55 of the low-priced generic drugs and formulations will cost $9 to
Walmart Inc.
Wal-Mart's aggressive rollout of generic drugs at $4 for a 30-day supply in 49 states, including Minnesota, is shaking the retail pharmacy market. The move, which could save consumers hundreds of dollars a month, has raised concerns from independent pharmacists who fear it may undermine the role of
Discount stores
Wal-Mart's expansion of its $4 generic prescription drug program to 83 Wisconsin pharmacies marks a significant shift in the state's retail pharmacy landscape. Starting Tuesday, the company's pharmacies will offer a wide range of generic prescriptions at a discounted price, following the company'
Discount stores
As of tomorrow, Wal-Mart's 131 pharmacies in Pennsylvania will join the chain's $4 generic prescription program, expanding the initiative to 811 pharmacies across 20 states. This move comes after Target Corp. announced a similar program in its pharmacies and BJ's Wholesale Club introduced a
Pharmaceutical industry
Wal-Mart's announcement that it will offer hundreds of generic drugs at $4 per month is a significant boost to the self-pay model of health-care delivery, according to Frank Sloan, a health economist at Duke University. This model can lower insurance premiums and increase a patient's role
Pharmaceutical industry
Codexis, Inc. has completed a $37 million Series D financing round, led by Bio*One Capital Pte Ltd of Singapore, with existing investors participating. This brings Codexis' total funding to $72 million, with an additional $3 million expected to be raised in the next 60 days. The company plans
